Category: ReShape Medical
The FDA lets San Clemente, Calif.-based ReShape Medical skip an advisory committee meeting for its obesity balloon device, CEO Richard Thompson tells MassDevice.com.
ReShape Medical, which is developing a balloon system to combat obesity, notched a significant victory in its path to commercialization, CEO Richard Thompson told MassDevice.com today.
Regulators at the FDA waived a requirement that the San Clemente, Calif.-based company appear before an advisory committee for its premarket approval application, Thompson told us. That removes a significant amount of uncertainty from the arduous PMA process for the ReShape Duo device, he said.
San Clemente, Calif.-based medical device maker ReShape Medical nets nearly $7 milllion from existing investors.
ReShape Medical, the medical device maker developing a balloon system to combat obesity has raised nearly $7 million through a debt financing round, according to regulatory filings.
The ECRI Institute releases its watch list of 10 technologies hospital C-suite executives should look out for in 2015.
Automated robotic systems used to combat hospital-acquired infections topped the ECRI Institute’s "2015 Top 10 Hospital C-Suite Watch List," an annual report on technologies healthcare executives should look out for in the next year to 18 months.
A Q&A with ReShape Medical CEO Richard Thompson on the company's cash pay procedure and how it can make a dent in obese patients.
There doesn't seem to be much stopping the obesity epidemic in the U.S., with ⅓ of the population considered dangerously overweight – but not for lack of trying, as evidenced by a glut of diets, pills, programs and surgeries aimed at helping people lose weight.
BioVentrix reports a $12.4 million funding round for its Revivent myocardial anchoring treatment for heart failure.
MASSDEVICE ON CALL — BioVentrix reported a $12.4 million funding round for its Revivent heart failure treatment.
San Ramon, Calif.-based BioVentrix said in an equity filing that the equity round, involving 195 unnamed investors, began Jan. 24 and closed today.
California device maker ReShape Medical closes enrollment in a pivotal trial of its ReShape Duo intra-gastric balloon, a non-surgical weight-loss system.
San Clemente, Calif.-based ReShape Medical closed pivotal trial enrollment for its ReShape Duo non-surgical weight-loss system, the company announced this week.
ReShape's Duo system is comprised of dual intra-gastric balloons that are placed in the stomach non-surgically via an endoscope inserted into the mouth. The balloons takes up space in the stomach to help patients feel full faster, causing them to eat smaller portions.
ReShape Medical raises $16 million in an equity round it hopes will wind up adding $22 million to its coffers for its dual-intragastric weight loss balloon.
ReShape Medical reeled in $15.8 million of a hoped-for $21.5 million funding round from a group of 7 unnamed investors, according to a regulatory filing.
The San Clemente, Calif.-based medical device company is developing a non-surgical weight loss device, the ReShape Duo, to treat obese patients. The device is a dual balloon designed to take up space in the stomach to reduce its capacity for food.